Fig. 1.

A timeline of MPO from discovery, function, inhibition, and disease. References indicated have been added for the seminal or foundational publication or first reports. References used to create the timeline: Peroxidase staining [4,5,18], Discovery [19] bactericidal activity [9]; MPO as % dry protein [20]; cells and cellular location [21]; Halogenation as bactericidal mechanism [11,22]; Anti-neutrophil cytoplasmic antibodies are anti-MPO [[23], [24], [25]]; MPO in atherosclerosis [26,27]; cardiotoxicity [[28], [29], [30], [31]]; neurotoxicity [32,33]; drug metabolism [[34], [35], [36]]; requirement for neutrophil extracellular trap formation [37,38]; MPO clinical inhibitor leads [[39], [40], [41]]; MPO levels in COVID-19 and thrombosis events [[42], [43], [44]].